Alkermes plc Stock
Price
Target price
€24.60
€24.60
-2.380%
-0.6
-2.380%
€37.60
05.09.25 / Stuttgart Stock Exchange
WKN: A1JKVH / Symbol: ALKS / Name: Alkermes / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Alkermes plc Stock
A loss of -2.380% shows a downward development for Alkermes plc.
Alkermes plc is currently one of the favorites of our community with 15 Buy predictions and no Sell predictions.
As a result the target price of 37 € shows a very positive potential of 50.41% compared to the current price of 24.6 € for Alkermes plc.
Pros and Cons of Alkermes plc in the next few years
Pros
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
B****
?
M***** P*******
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alkermes plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alkermes plc | -2.380% | 0.000% | 7.895% | 2.500% | -12.143% | 0.102% | 79.562% |
| Icon plc | 0.430% | -1.907% | 3.972% | -47.261% | -27.397% | -28.952% | - |
| Novocure Ltd | 0.630% | -0.664% | 6.194% | -30.514% | -64.028% | -86.751% | -84.500% |
| Ironwood Pharmaceuticals | -11.540% | -17.857% | 35.294% | -78.199% | -78.095% | -91.575% | -88.354% |
Comments
Alkermes plc (NASDAQ: ALKS) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $45.00 price target on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes plc (NASDAQ: ALKS) is now covered by analysts at The Goldman Sachs Group, Inc.. They set a "buy" rating and a $43.00 price target on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes plc (NASDAQ: ALKS) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $42.00 price target on the stock, up previously from $33.00.
Show more
Ratings data for ALKS provided by MarketBeat
News
Alkermes Q2 Sales Up 14 Percent
Alkermes Plc (NASDAQ:ALKS), a neuroscience-focused biopharmaceutical company, released its second quarter 2025 results on July 29, 2025. The standout news was a significant outperformance versus
